BASF Ends Its Pursuit of Evonik After Two Rejected Cash Offers

The takeover premium left Evonik's shares in one afternoon, and BASF chose valuation discipline over a third, higher bid.

Sources

Sources & evidence

What “Source checked” means

BASF said on Thursday it will end its efforts to acquire Evonik after the rival chemical maker rejected two non-binding all-cash offers.

BASF announced the decision on Thursday in its own release. The pursuit that began in September is over.

The second offer valued Evonik at about 11.2 billion euros, or $12.3 billion. That works out to 24 euros per share, Reuters reported.

Dow Jones put the same offer at 11.18 billion euros, or $12.27 billion. Its figure uses FactSet share-count data at 24 euros per share.

Why BASF walked away

BASF said it had signaled it could consider a further moderate increase. Even so, it said Evonik's board showed no meaningful engagement.

The company also questioned the price itself. Its assessment of Evonik's standalone prospects and risks did not justify paying more.

BASF said a higher price would not serve its shareholders. That judgment, not financing, ended the pursuit.

"We are convinced that BASF's derisked all-cash offer of 24 euros per share would have represented significant additional value for Evonik shareholders," said Dr. Markus Kamieth, BASF's chairman.

Kamieth added that BASF still believes the combination would create a more powerful chemical company. He said it would add value for shareholders and benefit employees and customers.

Under its Winning Ways strategy, BASF calls acquisitions a "could do," not a "must do." Walking away underlines its commitment to disciplined capital allocation, it said.

A courtship that never became talks

BASF first approached Evonik in September, Reuters reported. Evonik rejected a first offer, then rejected the raised offer as well.

Last month, Evonik said it would not enter negotiations. It said it was focused on delivering its standalone strategy instead.

Evonik's executives were willing to explain their position only on an informational, confidential basis. BASF said at the time it was surprised by that stance.

On Tuesday, BASF was preparing to offer greater concessions, people familiar with the matter told Reuters. The effort went beyond price.

BASF approached the North Rhine-Westphalia state government and the RAG Foundation, Evonik's top shareholder. Its letter floated possible commitments on plants, jobs and training.

Kamieth had argued last month for a stronger German chemical industry. He presented it as the right response to competition from Asia and the Middle East.

He had also vowed to respect Evonik's existing labor agreements. He ruled out compulsory redundancies until 2032 as part of a bigger group.

Evonik did not immediately respond to a request for comment on Thursday, Dow Jones reported.

The premium comes out

Evonik shares fell 17% in European afternoon trading on Thursday. They traded at 18.14 euros, Dow Jones reported.

That is roughly the level before BASF's interest became public in September. The takeover premium built since then left the stock in one afternoon.

BASF shares were up slightly in afternoon trading, Dow Jones reported. No percentage is printed here because the available readings conflict.

What remains unknown

What remains unknown starts with Evonik's own account of Thursday. The company had not commented immediately, and its fuller response is not yet on the record.

Whether Evonik's standalone strategy can rebuild the value the offer represented is unknown. So is whether another buyer will test the board's resolve.

How BASF will use the capital it chose not to spend is also unknown. The company pointed to attractive shareholder distributions without announcing anything new.

The tests that come next

The first test is Evonik's standalone delivery. Its results must now carry a share price that no longer holds a takeover premium.

The second test is BASF's discipline. Investors will watch whether the capital stays unspent or moves to smaller deals and distributions.

The third test is the German chemicals map. The combination Kamieth described will not happen, so both companies face Asian and Middle Eastern rivals separately.

Sources & evidence

Source checked3 sources · 5 figures

Figure receipts

Every figure in this article, with the source it came from.

  • 11.18 Evonik valuation under BASF's second offer, FactSet-based form

    EUR · As of Nov. 19, 2026

  • 17 Evonik share move, European afternoon trading Thursday

    EUR · As of Nov. 19, 2026

  • 18.14 Evonik share price, European afternoon trading Thursday

    EUR · As of Nov. 19, 2026

  • 11.2 Evonik valuation under BASF's second offer, Reuters form

    EUR · As of Nov. 19, 2026

  • 24 BASF second offer price per Evonik share

    EUR · euros per share - BASF's derisked all-cash offer price, per the BASF release · As of Nov. 19, 2026

As of Thursday, Nov. 19, 2026.

TickerGrove house illustration for deals coverage: stacked coins and a key

Get the Morning Brief — Weekday Morning Brief · Saturday Weekend Brief · Sunday Week Ahead

Discuss this story. Join TickerGrove on Discord to talk companies, earnings, and markets, or request future coverage.

Disclaimer

TickerGrove is education and journalism only. It is not investment advice, not a broker-dealer, and not a recommendation to buy, sell, or hold any security.

Nothing on this site is a pick or a return promise. Official economic prints and company filings are dated observations. External quote links open a separate service; TickerGrove does not host those prices.

Companies · All stories